Nectar Lifesciences witnessed a substantial acquisition as Rajasthan Global Securities Private Limited, along with its person acting in concert (PAC) LRSD Securities Private Limited, increased their combined stake in the pharmaceutical company. The acquisition involved the purchase of 3,62,422 equity shares through open market transactions, representing 0.16% of the company's total voting capital.

Acquisition Details

The transaction details reveal a strategic increase in shareholding by the acquirer group. Prior to this acquisition, Rajasthan Global Securities and LRSD Securities collectively held 1,10,07,830 shares, representing 4.91% of Nectar Lifesciences' voting capital.

Regulatory Compliance

The acquisition triggered disclosure requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the combined holding of the acquirer and PAC crossed the 5% threshold.

Company Capital Structure

Nectar Lifesciences maintains a consistent equity share capital structure throughout the transaction period. The company's capital details show:

Acquirer Information

Rajasthan Global Securities Private Limited serves as the primary acquirer, with LRSD Securities Private Limited acting as the person acting in concert. Both entities do not belong to the promoter or promoter group of Nectar Lifesciences. The acquisition was executed through open market purchases, indicating a strategic investment decision by the acquirer group.

The transaction represents a notable development in Nectar Lifesciences' shareholding pattern, with the acquirer group now holding a significant stake above the 5% regulatory threshold. The disclosure ensures transparency and compliance with SEBI regulations governing substantial acquisitions in listed companies.

Nectar Lifesciences Limited has successfully completed its share buyback program, purchasing 3 crore equity shares at ₹27 per share for a total consideration of ₹81 crore. The buyback, which concluded on January 6, 2026, witnessed significant investor interest with oversubscription of 2.05 times the target amount.

Buyback Program Details

The company's tender offer period commenced on December 31, 2025, and closed on January 6, 2026. The buyback was executed through the designated stock exchange mechanism, with NSE serving as the designated exchange. Settlement of all accepted bids was completed by January 13, 2026, through the Indian Clearing Corporation Limited and NSE Clearing Limited.

Investor Response and Allocation

The buyback received an overwhelming response from shareholders, with 11,981 valid bids received for 6.16 crore equity shares, representing 205.22% of the shares offered for buyback. The response was particularly strong in both categories of shareholders.

Major Participants

Several institutional investors participated significantly in the buyback program. Rajasthan Global Securities Private Limited emerged as the largest participant, with their accepted shares representing 14.59% of the total buyback.

Impact on Capital Structure

Following the buyback completion, Nectar Lifesciences' paid-up share capital will reduce from ₹22.43 crore to ₹19.43 crore, subject to the extinguishment of the bought-back shares. The extinguishment process is currently underway and expected to complete by January 22, 2026.

Shareholding Pattern Changes

The buyback will result in an increase in promoter shareholding from 44.90% to 51.84%, while the total number of shares outstanding will decrease from 22.43 crore to 19.43 crore shares.

The successful completion of this buyback program demonstrates strong management confidence in the company's prospects and provides enhanced value to shareholders through the premium buyback price and improved shareholding concentration.